This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vertex (VRTX) Outperforms Industry Year to Date: Here's Why
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) is expected to benefit from several catalysts this year. The company is likely to achieve multiple clinical milestones in 2023 and 2024, both in its CF and non-CF portfolio.
Will Keytruda Remain Merck's (MRK) Key Top-Line Driver?
by Zacks Equity Research
With continued label expansion into new indications, particularly earlier-line launches, Merck's (MRK) Keytruda is expected to remain a key top-line driver.
Novavax (NVAX) Updated COVID Jab Effective Against Eris Variant
by Zacks Equity Research
In studies on small animals and primates, Novavax's (NVAX) updated monovalent COVID-19 vaccine generates a robust immune response against the currently dominating Eris variant.
The Zacks Analyst Blog Highlights Moderna, BioNTech, Novavax and Pfizer
by Zacks Equity Research
Moderna, BioNTech, Novavax and Pfizer are included in this Analyst Blog.
U.S. Govt to Urge Citizens to Get New COVID-19 Shots
by Zacks Equity Research
Shares of COVID-19 vaccine makers soared after reports suggest that the Biden administration will start a campaign urging citizens to vaccinate themselves with updated shots vaccine in the upcoming fall.
Moderna (MRNA) Updated COVID Jab Effective Against Eris Variant
by Zacks Equity Research
Moderna's (MRNA) updated monovalent COVID-19 vaccine generates a robust immune response against the dominating Eris variant and another rapidly spreading virus strain in a clinical study.
Can Moderna (MRNA) Diversify Beyond Its COVID-19 Jab Sales?
by Zacks Equity Research
With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next three years.
Moderna (MRNA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Moderna (MRNA) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Moderna (MRNA) Beats on Q2 Earnings & Sales, Raises '23 View
by Zacks Equity Research
Moderna (MRNA) beats expectations for earnings and sales. Management raises its product revenue guidance based on potential U.S. demand for COVID vaccines during the upcoming fall season.
Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 5.73% and 18.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Moderna (MRNA) Ahead of Earnings?
by Zacks Equity Research
Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Merck (MRK) Beats on Q2 Earnings and Sales, Ups 2023 View
by Zacks Equity Research
Merck (MRK) beats Q2 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.
Moderna (MRNA) to Report Q2 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.
ANI Pharmaceuticals (ANIP) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
ANI Pharmaceuticals' (ANIP) second-quarter 2023 performance is likely to have been driven by rising generic and rare disease product revenues.
ADMA Biologics (ADMA) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
On ADMA Biologics' (ADMA) Q2 earnings call, investors will likely focus on the sales performance of its immune deficiency disorder drugs.
Moderna (MRNA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $120.65, marking a -1% move from the previous day.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
AstraZeneca (AZN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga, are likely to have driven sales, partially offset by lower sales of legacy drugs.
GSK Gears Up for Q2 Earnings: Will It Surpass Estimates?
by Zacks Equity Research
We expect GSK's specialty products like Cabenuva, Dovato, Bexsero, Breo Ellipta and Shingrix to drive second-quarter sales performance.
Moderna (MRNA) Stock Moves -0.32%: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $124.77 in the latest trading session, marking a -0.32% move from the prior day.
Biogen (BIIB) to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
Biogen's sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.
J&J (JNJ) to Begin Q2 Earnings Season for Drug, Biotech Sector
by Zacks Equity Research
Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex. In the MedTech segment, recovery in surgical procedures and new product launches are likely to have pushed sales growth.
Moderna (MRNA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $126.62, marking a +0.56% move from the previous day.
Novavax's (NVAX) COVID Jab Gets Full Approval in Europe
by Zacks Equity Research
Novavax's (NVAX) protein-based COVID-19 vaccine, Nuvaxovid, gets full marketing authorization for COVID patients in Europe.
Company News for Jul 7, 2023
by Zacks Equity Research
Companies in The News Are: JBLU, AAL, F, MRNA, GENI.